Research on genetic profiling and its clinical significance using clinical specimens from cancer patients

Research on genetic profiling and its clinical significance using clinical specimens from cancer patients - CONDUCTOR study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049066

Enrollment

700

Registered

2022-09-29

Start date

2022-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumors There are no restrictions on the type of cancer, although breast cancer, lung cancer, and gastrointestinal cancer are covered.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 4.1 Eligibility Criteria 1. be at least 18 years of age at the time of consent 2. cancer patients who are being or may be considered for treatment with antineoplastic agents at the participating institution 3) Patients for whom one or more of the following samples, which can be analyzed genetically, can be obtained i. Tumor tissue (i) Surplus biopsy specimens (frozen specimens) collected during medical treatment (ii) Surplus specimens of surgical specimens (frozen specimens) (iii) Specimens collected in clinical trials* related to this study (frozen specimens) ii. Non-tumor tissue (iv) Specimens collected in clinical trials* related to this study (frozen specimens) (v) New peripheral blood samples (up to 13 mL) to be collected for this study (Vii)Peripheral blood samples (up to 7 mL) newly collected for plasma proteome and plasma metabolome analysis in this study. (viii)Fecal samples newly collected for this study. (ix)Saliva samples newly collected for this study. (*) Relevant clinical trials include the ENSEMBLE study, a clinical trial of perioperative treatment of rectal cancer. 4.Written consent for participation in this study has been obtained.

Exclusion criteria

Exclusion criteria: 1. the physician in charge determines that the subject is not suitable for enrollment in this study, taking into consideration the subject's physical and mental condition, etc.

Design outcomes

Primary

Measure	Time frame
In order to deliver high quality medical care to the public and to "conquer cancer" in the future, we will strategically accumulate the results of whole genome analysis and other analyses, and promote their use in research and drug discovery. In addition, genetic profiling using clinical specimens and its clinical significance will be discussed.	—

Countries

Japan

Contacts

Public ContactHideaki Bando

National Cancer Center Hospital East Department of Colorectal Surgery

conductor_jimukyoku@east.ncc.go.jp0471331111

Outcome results